Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-05-18
DOI
10.3389/fimmu.2022.903679
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Harnessing cytokines and chemokines for cancer therapy
- (2022) David J. Propper et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
- (2022) Xiaozhen Zhang et al. Journal for ImmunoTherapy of Cancer
- Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy
- (2021) Tamir Baram et al. Frontiers in Oncology
- Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors
- (2021) Tamir Baram et al. Cells
- A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer
- (2021) Mengmeng Jiang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The effects of TNF ‐α/ TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer
- (2021) Yang Qu et al. INTERNATIONAL JOURNAL OF CANCER
- The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
- (2020) Daniel Cruceriu et al. CELLULAR ONCOLOGY
- TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients
- (2020) Maya Dadiani et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TNFR2 blockade alone or in combination with PD‐1 blockade shows therapeutic efficacy in murine cancer models
- (2020) Katherine Case et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer
- (2020) María Florencia Mercogliano et al. Frontiers in Oncology
- Selective Targeting of TNF Receptors as a Novel Therapeutic Approach
- (2020) Roman Fischer et al. Frontiers in Cell and Developmental Biology
- Immunocytokines are a promising immunotherapeutic approach against glioblastoma
- (2020) Tobias Weiss et al. Science Translational Medicine
- Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update
- (2020) Isaac J. Powell et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Role of inflammation in the development of colorectal cancer
- (2020) Sridhar Muthusami et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- (2020) Anne Montfort et al. CLINICAL CANCER RESEARCH
- Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study
- (2020) Karin Hellgren et al. RHEUMATOLOGY
- Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects
- (2020) Portia Gough et al. Frontiers in Immunology
- Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer
- (2020) Ling He et al. NEOPLASIA
- Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment
- (2020) Ke Gong et al. NEOPLASIA
- The TNF Paradox in Cancer Progression and Immunotherapy
- (2019) Anne Montfort et al. Frontiers in Immunology
- Partners in crime: TNFα-based networks promoting cancer progression
- (2019) Adit Ben-Baruch CANCER IMMUNOLOGY IMMUNOTHERAPY
- Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
- (2018) Yuehong Chen et al. CYTOKINE
- Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity
- (2018) Barbara Ziffels et al. Immunotherapy
- A New Venue of TNF Targeting
- (2018) Sophie Steeland et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Simultaneous stimulation with tumor necrosis factor-α and transforming growth factor-β1 induces epithelial-mesenchymal transition in colon cancer cells via the NF-κB pathway
- (2018) Yuanfei Li et al. Oncology Letters
- The Significance of Tumor Necrosis Factor Receptor Type II in CD8+ Regulatory T Cells and CD8+ Effector T Cells
- (2018) Lin-Lin Ye et al. Frontiers in Immunology
- Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis
- (2018) Pauline Raaschou et al. ANNALS OF INTERNAL MEDICINE
- Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome
- (2018) H Torrey et al. LEUKEMIA
- TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage
- (2017) Fuqian Yang et al. Molecular Medicine Reports
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- TNFR2: A Novel Target for Cancer Immunotherapy
- (2017) Éva S. Vanamee et al. TRENDS IN MOLECULAR MEDICINE
- Cancer Inflammation and Cytokines
- (2017) Maria Rosaria Galdiero et al. Cold Spring Harbor Perspectives in Biology
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment
- (2017) Yang Qu et al. Frontiers in Immunology
- TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
- (2016) Mamta Gupta et al. HUMAN PATHOLOGY
- Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors
- (2016) Polina Weitzenfeld et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells
- (2016) Polina Weitzenfeld et al. Oncotarget
- Inflammation and cancer: advances and new agents
- (2015) Shanthini M. Crusz et al. Nature Reviews Clinical Oncology
- Systemic use of tumor necrosis factor alpha as an anticancer agent
- (2015) Nicholas J. Roberts et al. Oncotarget
- Targeting Transmembrane TNF-α Suppresses Breast Cancer Growth
- (2013) Mingxia Yu et al. CANCER RESEARCH
- Inflammation and ovarian cancer
- (2012) Antonio Macciò et al. CYTOKINE
- Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
- (2012) James W. Antoon et al. Scientific Reports
- TNF inhibitor suppresses bone metastasis in a breast cancer cell line
- (2011) Takahiko Hamaguchi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition
- (2011) Gali Soria et al. BMC CANCER
- Tumor necrosis factor receptor cross-talk
- (2011) Petrus J. W. Naudé et al. FEBS Journal
- The chemokine system and cancer
- (2011) Frances R Balkwill JOURNAL OF PATHOLOGY
- Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells
- (2010) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
- (2009) F. Colotta et al. CARCINOGENESIS
- A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
- (2008) E. R. Brown et al. ANNALS OF ONCOLOGY
- TNF: A master switch for inflammation to cancer
- (2008) Gautam Sethi Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search